Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-217014 SCHEMBL8306389 | 1.00 | TSHR (0.35) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL12021494 | 0.83 | CYP1A2 (0.34) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL8344819 | 0.83 | CYP1A2 (0.38) | LMNACYP1A2ALDH1A1MGAMGAA | |
| SCHEMBL14559622 | 0.83 | CYP1A2 (0.38) | LMNACYP1A2ALDH1A1MGAMGAA | |
| SCHEMBL14559637 | 0.82 | CYP1A2 (0.46) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL16314979 | 0.79 | TSHR (0.50) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL14559635 | 0.78 | TP53 (0.34) | TSHRALDH1A1TP53MGAMGAA | |
| SCHEMBL23355288 | 0.77 | CYP1A2 (0.53) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL3152370 | 0.77 | CYP1A2 (0.53) | TSHRLMNASMN1; SMN2CYP1A2USP2 | |
| SCHEMBL5388086 | 0.77 | CYP1A2 (0.53) | TSHRLMNASMN1; SMN2CYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | claimed |
| US-20250382671-A1 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN CIRCULATING BODILY FLUIDS | Brain Chemistry Labs (US) | 2025-12-18 | — | — | US | claimed |
| EP-4287941-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2023-12-13 | — | — | EP | claimed |
| EP-4069868-A2 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2022-10-12 | — | — | EP | claimed |
| US-20220252620-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs | 2022-08-11 | — | — | US | claimed |
| WO-2022168006-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs (US) | 2022-08-11 | — | — | WO | claimed |
| US-20260108484-A1 | TREATMENT OF NEUROPATHIC PAIN IN CANINES | TRIVIUMVET DESIGNATED ACTIVITY COMPANY (IE) | 2026-04-23 | — | — | US | disclosed |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250382671-A1 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN CIRCULATING BODILY FLUIDS | Brain Chemistry Labs (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4640276-A2 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | Board Of Regents, The University Of Texas System (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3972593-B1 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | UNIV TEXAS (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4287941-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4069868-A2 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11433081-B2 | Compositions and methods for pain management | LoMed, Inc. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220252620-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs | 2022-08-11 | — | — | US | disclosed |
| WO-2022168006-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220226321-A1 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3972593-A1 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | Board of Regents, The University of Texas System (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108484-A1 | TREATMENT OF NEUROPATHIC PAIN IN CANINES | SMN1; SMN2, CACNA1S, CACNA1C | TSHR 4465/4885LMNA 469/4885SMN1; SMN2 1/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | TSHR 331/4885LMNA 4153/4885SMN1; SMN2 1535/4885 |
| US-20220226321-A1 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | NCKAP1, CAMKK2, CAMKK1 | TSHR 4847/4885LMNA 4498/4885SMN1; SMN2 65/4885 |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | COMT, MAOB, ACHE | TSHR 3435/4885LMNA 1097/4885SMN1; SMN2 1717/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | TSHR 331/4885LMNA 4153/4885SMN1; SMN2 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.